Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axatilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Axatilimab overview

Axatilimab (SNDX-6352) is under development for the treatment of graft versus host disease, solid tumours including intrahepatic cholangiocarcinoma, relapsed and refractory Hodgkin Lymphoma and idiopathic pulmonary fibrosis. It is administered intravenously as solution for infusion. The drug candidate is a humanized IgG4 monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R). It was under development for Coronavirus disease 2019 (COVID-19).

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops, and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the treatment of non-small cell lung cancer, and melanoma, ovarian cancer and other indications. The company has an operational presence in the UK. Syndax is headquartered in Waltham, Massachusetts, the US.

For a complete picture of Axatilimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.